Compile Data Set for Download or QSAR
Report error Found 306 Enz. Inhib. hit(s) with all data for entry = 11106
TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590790(US11564928, Compound 37 | 6-(5-fluoropyridin-2-yl)...)
Affinity DataIC50: 0.600nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590808(US11564928, Compound 55 | 6-(5-(difluoromethoxy)py...)
Affinity DataIC50: 0.600nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590781(US11564928, Compound 28 | 6-(4-methoxyphenyl)-1-(2...)
Affinity DataIC50: 0.700nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590785(US11564928, Compound 32 | 6-(4-fluorophenyl)-1-(2-...)
Affinity DataIC50: 0.800nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590787(US11564928, Compound 34 | 1-(2-morpholinoethyl)-2-...)
Affinity DataIC50: 1nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590782(US11564928, Compound 29 | 6-(4-methoxyphenyl)-1-(2...)
Affinity DataIC50: 1.20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590792(US11564928, Compound 39 | N-(4,4-dimethylcyclohexy...)
Affinity DataIC50: 1.20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590783(US11564928, Compound 30 | N-(1-(4-fluorophenyl)eth...)
Affinity DataIC50: 1.20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590780(US11564928, Compound 27 | N-(4,4-difluorocyclohexy...)
Affinity DataIC50: 2nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590804(US11564928, Compound 51 | 6-(4-(difluoromethoxy)ph...)
Affinity DataIC50: 2.10nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590779(US11564928, Compound 26 | N-(4,4-dimethylcyclohexy...)
Affinity DataIC50: 2.20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590852(US11564928, Compound 102 | 1-(4-fluorobenzyl)-6-(o...)
Affinity DataIC50: 2.30nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590853(US11564928, Compound 103 | (R)-1-(4-fluorobenzyl)-...)
Affinity DataIC50: 3nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590846(US11564928, Compound 95 | (R)-N-(1-(4-cyanophenyl)...)
Affinity DataIC50: 3.20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590844(US11564928, Compound 93 | 6-cyclopropyl-1-(4-fluor...)
Affinity DataIC50: 3.60nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590835(US11564928, Compound 84 | N-(bicyclo[1.1.1]pentan-...)
Affinity DataIC50: 3.70nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590786(US11564928, Compound 33 | 6-(2,3-dihydrobenzo[b][1...)
Affinity DataIC50: 4nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590850(US11564928, Compound 100 | (R)-N-(1-(4-fluoropheny...)
Affinity DataIC50: 4nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590845(US11564928, Compound 94 | (R)-6-cyclopropyl-1-(4-f...)
Affinity DataIC50: 4.10nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590803(US11564928, Compound 50 | N-(bicyclo[1.1.1]pentan-...)
Affinity DataIC50: 4.30nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590801(US11564928, Compound 48 | (R)-6-(5-(difluoromethox...)
Affinity DataIC50: 4.5nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590773(US11564928, Compound 20 | 4-hydroxy-6-(4-methoxyph...)
Affinity DataIC50: 4.70nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590789(US11564928, Compound 36 | 6-(5-cyanopyridin-2-yl)-...)
Affinity DataIC50: 5nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590838(US11564928, Compound 87 | (R)-6-bromo-1-(4-fluorob...)
Affinity DataIC50: 5nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590832(US11564928, Compound 81 | 6-bromo-1-(4-fluorobenzy...)
Affinity DataIC50: 5nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590811(US11564928, Compound 58 | 6-(5-cyanopyridin-2-yl)-...)
Affinity DataIC50: 5.58nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590799(US11564928, Compound 46 | N-(bicyc1o[1.1.1]pentan-...)
Affinity DataIC50: 6nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590759(US11564928, Compound 6 | 6-(4-fluorophenyl)-4-hydr...)
Affinity DataIC50: 6.10nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590758(US11564928, Compound 5 | 6-(4-fluorophenyl)-4-hydr...)
Affinity DataIC50: 6.5nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590839(US11564928, Compound 88 | (R)-1-(4-fluorobenzyl)-N...)
Affinity DataIC50: 6.70nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590793(US11564928, Compound 40 | 6-(5-cyanopyridin-2-yl)-...)
Affinity DataIC50: 7nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590842(US11564928, Compound 91 | (R)-6-bromo-N-(1-(4-cyan...)
Affinity DataIC50: 7nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590763(US11564928, Compound 10 | 4-hydroxy-6-(4- methoxy...)
Affinity DataIC50: 7nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590797(US11564928, Compound 44 | 6-(4-cyanophenyl)-1-(2-m...)
Affinity DataIC50: 7.20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590788(US11564928, Compound 35 | 1-(2-morpholinoethyl)-2-...)
Affinity DataIC50: 7.5nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590851(US11564928, Compound 101 | (R)-N-(1-(4-cyanophenyl...)
Affinity DataIC50: 7.60nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590836(US11564928, Compound 85 | (R)-N-(1-(4-cyanophenyl)...)
Affinity DataIC50: 7.90nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590768(US11564928, Compound 15 | 6-(4-(difluoromethoxy)ph...)
Affinity DataIC50: 8.80nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590870(US11564928, Compound 121 | 6-(4-fluorophenyl)-4-hy...)
Affinity DataIC50: 9nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590805(US11564928, Compound 52 | 6-(4-(difluoromethoxy)ph...)
Affinity DataIC50: 10nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590841(US11564928, Compound 90 | (S)-6-bromo-1-(4-fluorob...)
Affinity DataIC50: 11nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590849(US11564928, Compound 99 | 6-bromo-1-((5-fluoropyri...)
Affinity DataIC50: 12nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590855(US11564928, Compound 105 | N-(4-fluorobenzyl)-6-(4...)
Affinity DataIC50: 14nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590886(US11564928, Compound 137 | 4-hydroxy-N-((1s,4s)-4-...)
Affinity DataIC50: 15nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590766(US11564928, Compound 13 | N-(bicyclo[1.1.1]pentan-...)
Affinity DataIC50: 17nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590761(US11564928, Compound 8 | N-(bicyclo[1.1.1]pentan-1...)
Affinity DataIC50: 20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590772(US11564928, Compound 19 | 6-(2,3-dihydrobenzo[b][1...)
Affinity DataIC50: 20nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590769(US11564928, Compound 16 | 6-(4-cyanophenyl)-4-hydr...)
Affinity DataIC50: 22.6nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590795(US11564928, Compound 42 | 6-(5-cyanopyridin-2-yl)-...)
Affinity DataIC50: 23nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

TargetCannabinoid receptor 2(Human)
Teon Therapeutics

US Patent
LigandPNGBDBM590800(US11564928, Compound 47 | 6-(5-(difluoromethoxy)py...)
Affinity DataIC50: 24.9nMAssay Description:CB1R binding protocol involves the use of the same solution buffer used for both incubation and washing reaction (Tris-HCl, 50 mM; EDTA, 2.5 mM; MgCl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/19/2023
Entry Details
US Patent

Displayed 1 to 50 (of 306 total ) | Next | Last >>
Jump to: